Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer

Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT07738172 by National Taiwan University Hospital, with a registry enrolment figure of 154 participants, started 2026-09-08 and due to reach its primary completion in 2031-08-01. Interventions recorded: Primary Tumor Resection; Osimertinib. Conditions listed: Lung Neoplasms, Non-Small Cell Lung Cancer. Primary outcome: Progression-Free Survival. Lung eligibility wording from the registry: "Patients must meet the baseline eligibility criteria, including stage IV NSCLC, EGFR sensitizing mutation (exon 19 deletion or L858R), resectable dominant primary lung lesion, and adequate performance status and organ function". Sites: Taiwan. No results are recorded here; the registry entry is the source.